ArticleTranslational lung cancer research2025
Radiomic phenotypes of oligometastatic non-small cell lung cancer.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Treatment of oligometastatic lung cancers: new data, new drivers, new approaches.BMJ oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Background: Identifying biomarkers that optimize patient selection for ablative therapy in metastatic non-small cell lung cancer (NSCLC) remains an unmet need. In this study, we identified radiomic features associated with sustained oligometastatic and indolent NSCLC. Methods: We curated a retrospective cohort of 167 patients (132 training/validation, 35 test) with treatment-naïve, metastatic NSCLC and pre-treatment positron emission tomography/computed tomography (PET/CT). We extracted radiomic features from the primary lesion and used Pearson's correlation to identify those associated with extent of metastatic disease. For a subset (n=83), we also identified features associated with overall survival (OS) using Cox proportional hazards models. Results: We found that the inverse flatness was lower (r=-0.23; q=0.04) and surface area-to-volume ratio (SVR) was higher (r=0.24; q=0.04) in primary lesions for cases with more metastases. We further found that higher gray level variance on CT portends shorter OS [hazard ratio (HR) =1.84, 95% confidence interval (CI): 1.32-2.56, q=0.004; test c=0.74, 95% CI: 0.52-0.90]. Risk groups derived from these scores exhibited median survival times in the training set of 12.6 and >50 months (P=0.001) and in the test set of 13.8 and 32.7 months (P=0.06). This feature was determined primarily by inclusion of low-intensity voxels. Conclusions: This study identifies radiomic features of indolent NSCLC, demonstrating that flatter, higher surface area primary disease is associated with a greater number of metastases, and primary lesions with lower density representing lung parenchyma, airspace, or lower-density tumor portend shorter OS. These findings lay the groundwork toward identifying patients suitable for ablative radiotherapy despite the presence of metastatic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.